CALGARY, AB, Jan. 5, 2021 /CNW/ - Nanalysis Scientific
Corp. (Nanalysis, TSXV: NSCI OTCQX: NSCIF FRA: 1N1), is
pleased to announce that it has shipped the first four units of its
new 100 MHz product to customers. Current sales backlog of this
product is over $4.5 million and
growing.
Dr. Susanne Riegel, Director of
Marketing states "When Nanalysis entered the benchtop NMR market,
we quickly identified the customer need for such a high-end
product. Based on years of customer feedback, we have refined our
product specifications and are excited to release this innovative
product to address the demand. It has been extremely well
received and I am excited about its potential in pharma, biotech,
flavour and fragrance, personal care, advanced materials, security,
energy, and many other sectors and end markets."
Neal Gallagher, Director of
Product Development states "When marketing challenged our team to
develop the highest performing permanent magnet platform possible,
it became immediately clear that we had to throw out the standard
playbook and start our thinking from scratch. This approach allowed
us to really push the envelope in terms of considering how
magnetic, mechanical, electrical, and thermal systems could
interact. We overcame numerous materials and technical challenges
along the way culminating in the strongest most sensitive compact
permanent magnet platform in history. Never before has any
organization been able to establish a stable magnetic field of over
2.3 Tesla of spectroscopic quality on the benchtop and I think our
devotion to every aspect of the product will shine through in the
customer experience.
I am very proud of our magnet, electronics, software, and system
integration teams. Together, I believe we have achieved a landmark
new product, and our customers agree. We will continue to create
the most advanced products that enable our customers to solve ever
more exciting problems using NMR and create the chemistry of the
future - We are just getting started!"
Sean Krakiwsky, founder and CEO
of Nanalysis Scientific added, "Now that this product is shipping
to customers, I expect it to provide strong revenue growth going
forward. Our sales team and distributor network are very excited
about this product. Our manufacturing department has capacity to
fulfill the current order backlog in the near term and the sales
pipeline for the rest of the year is strong. Our Calgary and Strasbourg teams worked incredibly well
together on this project. The first critical test of our ability to
integrate RS2D's Cameleon4TM technology from last
March's acquisition and enhance our MRI and NMR technology platform
was a resounding success."
About Nanalysis Scientific
Corp. (TSXV: NSCI, OTCQX: NSCIF,
FRA:1N1)
Nanalysis trades on the TSX Venture Exchange (TSXV) in
Canada with ticker symbol 'NSCI'
,Over the Counter (OTC) in the United
States under the ticker symbol 'NSCIF', and on the Frankfurt
Exchange (FRA) under the symbol '1N1'.
Nanalysis is an international business focused on capitalizing
its proprietary technologies in nuclear magnetic resonance (NMR)
that go into NMR spectrometers and magnetic resonance imaging
(MRI). Nanalysis operates out of two subsidiaries, Nanalysis Corp.
and RS2D S.A.S. (RS2D).
Nanalysis Corp. is an industry leader in developing and
manufacturing compact NMR spectrometers for laboratory and
industrial markets. Its cutting edge 60 and 100 MHz spectrometers
require no liquid helium or other cryogens. Its spectrometers are
used by chemical professionals spanning industries, including, but
not limited to, oil and gas, chemical, mining, pharmaceutical, and
biotechnology.
Through its European subsidiary RS2D, the Company electronic
boards and software used to drive MRI equipment in pre-clinical
configurations and are being incorporated into next-gen MRI
systems.
Notice regarding Forward Looking Statements and Legal
Disclaimer
This news release contains certain "forward-looking statements"
within the meaning of such statements under applicable securities
law. Forward-looking statements are frequently characterized by
words such as "anticipates", "plan", "continue", "expect",
"project", "intend", "believe", "anticipate", "estimate", "may",
"will", "potential", "proposed", "positioned" and other similar
words, or statements that certain events or conditions "may" or
"will" occur. These statements are only predictions. Various
assumptions were used in drawing the conclusions or making the
projections contained in the forward-looking statements throughout
this news release. Forward-looking statements are based on the
opinions and estimates of management at the date the statements are
made and are subject to a variety of risks and uncertainties and
other factors that could cause actual events or results to differ
materially from those projected in the forward-looking statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services
Provider accepts responsibility for the adequacy or accuracy of
this release.
SOURCE Nanalysis Scientific Corp.